Eplivanserin

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameEplivanserin
Drug Alias Nameeplivanserina依利色林依普舍林eplivanserinumSliwens +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptor
Therapy Area/IndicationsSleepChronic PainSleep Initiation and Maintenance Disorders +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofi
Active IndicationsN/A
Inactive IndicationsSleepChronic PainSleep Initiation and Maintenance Disorders +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG